October 17, 2025

BioMed X launches Women’s Health R&D Accelerator in Heidelberg

BioMed X launches Women’s Health R&D Accelerator in Heidelberg
  • The first XFem Labs research project, supported by the Gates Foundation, aims to accelerate the development of non-hormonal contraceptives, in particular for women in low- and middle-income countries via BioMed X’s global talent sourcing and incubation model.

Heidelberg, Germany, October 14th, 2025. BioMed X, today announced the launch of XFem Labs, a new Women’s Health R&D Accelerator in Heidelberg. The purpose of this initiative, which is supported by the Gates Foundation, is to establish a world-class women’s health innovation hub that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.

Embedded within the academic environments of the University of Heidelberg and Yale, and directly within R&D campuses of leading pharmaceutical companies, BioMed X bridges the translational gap between academia and industry to drive transformative innovation.

The first project at the new XFem Labs accelerator in Heidelberg is entitled “New Strategies for Female-Controlled Non-Hormonal Contraception”. Despite the availability of various contraceptive methods, 257 million women worldwide still face significant barriers to access. Current hormonal contraceptives are often associated with side effects, such as changes in bleeding patterns, resulting in high discontinuation rates. Non-hormonal, female-controlled alternatives remain limited and often challenging, hence there is an urgent need for new options.

The first XFem Labs call for application invites proposals that explore new biological targets, molecular mechanisms, or delivery modalities for continuous and/or on-demand non-hormonal contraception. Selected researchers will participate in a boot camp at BioMed X, resulting in the incubation of a new research team based In Heidelberg.

“Our joint goal with the Gates Foundation is to create a significant impact on the lives and health of women world-wide,” said Dr. Christian Tidona, CEO of BioMed X. “Together with an international network of top experts and key opinion leaders, we will jointly build and mentor new outstanding research teams who will strive to solve some of the most pressing challenges in women’s health.”

Researchers interested in becoming part of this new research group are invited to respond to this international call by submitting a project proposal via the BioMed X Career Space at https://career.bmedx.com/call/2025-XFL-C01 before December 7, 2025.

This first XFem Labs project is made possible with a $2 million grant and network support from the Gates Foundation.

Our latest News

discover more
RHEACELL makes second location in Heidelberg visible

RHEACELL makes second location in Heidelberg visible

Heidelberg, January 28, 2026 – RHEACELL GmbH & Co. KG is continuing to expand its presence in Heidelberg and moved into a second location in the Pfaffengrund district in August last year. At the start of the year, the location is now also becoming visible to the outside world: this week, the company logo will […]

TUM Researchers receive two ERC Grants

TUM Researchers receive two ERC Grants

The European Research Council’s (ERC) Proof of Concept Grants are designed to help researchers turn their findings into real‑world innovations. Two ERC‑funded follow‑up projects at TUM will each receive approximately 150,000 euros in support. The projects focus on virus‑driven cancer treatments and new ways to supply electrons for enzyme‑based technologies. Researchers at TUM have secured […]

Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Weight Loss in Cancer: Organs Respond to the Disease in a Coordinated Way

Cachexia is a metabolic disorder that causes uncontrolled weight loss and muscle wasting in chronic diseases and cancer. A new study by Helmholtz Munich, in collaboration with the Institute of Physiology of the Czech Academy of Sciences in Prague, Heidelberg University Hospital, the German Center for Diabetes Research (DZD), and the German Center for Cardiovascular […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp